432 related articles for article (PubMed ID: 32277501)
21. Performance of factor IX extended half-life product measurements in external quality control assessment programs.
Nederlof A; Kitchen S; Meijer P; Cnossen M; Ali Pour N; Kershaw G; Jennings I; Walker I; de Maat MPM
J Thromb Haemost; 2020 Aug; 18(8):1874-1883. PubMed ID: 32311825
[TBL] [Abstract][Full Text] [Related]
22. Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
Nummi V; Jouppila A; Lassila R
Int J Lab Hematol; 2017 Aug; 39(4):359-368. PubMed ID: 28406575
[TBL] [Abstract][Full Text] [Related]
23. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
Van den Bossche D; Peerlinck K; Jacquemin M
Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
[TBL] [Abstract][Full Text] [Related]
24. Role of chromogenic assays in haemophilia A and B diagnosis.
Bowyer AE; Duncan EM; Antovic JP
Haemophilia; 2018 Jul; 24(4):578-583. PubMed ID: 29808946
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
Morfini M; Farrugia A
Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
[No Abstract] [Full Text] [Related]
26. Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
Alamelu J; Bevan D; Sorensen B; Rangarajan S
J Thromb Haemost; 2014 Dec; 12(12):2044-8. PubMed ID: 25315324
[TBL] [Abstract][Full Text] [Related]
27. Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVIII concentrates.
Pouplard C; Sattler L; Ryman A; Eschwege V; De Maistre E; Flaujac C; Szymezak J; Grand F; Repesse Y; Galinat H; Donnard M; Ternisien C; Iorio A; Chelle P; Jeanpierre E;
Haemophilia; 2020 Mar; 26(2):282-289. PubMed ID: 32107819
[TBL] [Abstract][Full Text] [Related]
28. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
29. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
30. Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.
Horn C; Négrier C; Kalina U; Seifert W; Friedman KD
J Thromb Haemost; 2019 Jan; 17(1):138-148. PubMed ID: 30418692
[TBL] [Abstract][Full Text] [Related]
31. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
[TBL] [Abstract][Full Text] [Related]
32. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
33. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.
Peyvandi F; Kenet G; Pekrul I; Pruthi RK; Ramge P; Spannagl M
J Thromb Haemost; 2020 Jun; 18(6):1242-1255. PubMed ID: 32115865
[TBL] [Abstract][Full Text] [Related]
34. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
[TBL] [Abstract][Full Text] [Related]
35. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
[TBL] [Abstract][Full Text] [Related]
36. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
Björkman S
Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
[TBL] [Abstract][Full Text] [Related]
38. Monitoring of modified factor VIII and IX products.
Kitchen S; Gray E; Mertens K
Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Preijers T; Hazendonk HCAM; Liesner R; Chowdary P; Driessens MHE; Hart D; Keeling D; Laros-van Gorkom BAP; van der Meer FJM; Meijer K; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH; Mathôt RAA;
J Thromb Haemost; 2018 Nov; 16(11):2196-2207. PubMed ID: 30394056
[TBL] [Abstract][Full Text] [Related]
40. Treatment on demand--in vivo dose finding studies.
Escobar MA
Haemophilia; 2003 Jul; 9(4):360-7. PubMed ID: 12828669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]